Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766319 | 0.90 | CSF1R (0.54) | RETBRAFTNNI3KEGFRCSF1R | |
| SCHEMBL4769675 | 0.88 | CHUK (0.48) | RETBRAFTNNI3KEGFRCSF1R | |
| SCHEMBL4769668 | 0.86 | BRAF (0.46) | RETBRAFTNNI3KEGFRKIT | |
| SCHEMBL4769455 | 0.85 | KDR (0.59) | RETEGFRCSF1RKIT | |
| SCHEMBL4763956 | 0.85 | KDR (0.50) | RETEGFRCSF1RKIT | |
| SCHEMBL4766961 | 0.84 | CSF1R (0.61) | RETEGFRCSF1RKITAURKB | |
| SCHEMBL4768505 | 0.78 | EGFR (0.54) | RETEGFRCSF1RKIT | |
| SCHEMBL4765608 | 0.77 | EGFR (0.52) | RETBRAFEGFRAURKB | |
| SCHEMBL4764388 | 0.76 | PIK3CA (0.48) | RETBRAFTNNI3KEGFRCSF1R | |
| SCHEMBL4763947 | 0.75 | PRMT5 (0.64) | EGFRAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | disclosed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | RET 1707/4885BRAF 326/4885TNNI3K 2235/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | RET 2696/4885BRAF 929/4885TNNI3K 2666/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | RET 2836/4885BRAF 1116/4885TNNI3K 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.